Leland Stanford Junior University

Northwestern University

Joel T Dudley

Atul J Butte

Michael P Snyder

Irina Budunova

Konrad Karczewski

Gleb Baida

J Michael Cherry

Julie Park

Alexander A Morgan

Eurie Hong

Alan Boyle

Disclosed are methods and pharmaceutical compositions for treating diseases, disorders, and conditions associated with glucocorticoid receptor (GR) expression and activity. The disclosed methods typically include administering to a patient in need thereof a glucocorticoid receptor (GR) agonist and administering to the patient in need thereof a REDD1 inhibitor that inhibits expression or activity of REDD1, wherein the REDD1 inhibitor is administered before, concurrently with, or after the GR agonist is administered.

Use of REDD1 inhibitors to dissociate therapeutic and adverse atrophogenic effects of glucocorticoid receptor agonists

Measuring of the binding of a transcription factor (using, for example, chromatin immunoprecipitation) according to the present invention is provides an improved marker for a disease. These markers can be used in diagnostics for diseases where a transcription factor binding event plays a role. Additionally, they can be used to adjust disease risk profiles for healthy individuals as with typical genetic variants.

Method and system for the use of biomarkers for regulatory dysfunction in disease

Methods and systems are provided for the computation and display of an individual's personalized health risk based on the genome sequence of the individual, known etiological interactions between diseases for which the individual is determined to have genetic risk factors, and environmental etiological factors associated with the same diseases that represent potentially modifiable disease risk modifiers.

Method and system for computing and integrating genetic and environmental health risks for a personal genome

Growing community of inventors

San Jose, CA, United States of America

Joel T Dudley